Jim Simons Intellia Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 38,700 shares of NTLA stock, worth $647,451. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,700

Holding current value

$647,451

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$20.02 - $27.22 $774,774 - $1.05 Million	38,700 New	38,700 $866,000
Q4 2023 Feb 13, 2024	BUY	$23.16 - $32.34 $310,274 - $433,258	13,397 New	13,397 $408,000
Q1 2023 May 12, 2023	BUY	$33.3 - $44.82 $551,248 - $741,950	16,554 New	16,554 $617,000
Q2 2022 Aug 12, 2022	BUY	$38.49 - $76.21 $4.6 Million - $9.11 Million	119,600 New	119,600 $6.19 Million
Q3 2020 Nov 13, 2020	SELL	$17.47 - $24.93 $716,270 - $1.02 Million	-41,000 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$11.14 - $22.87 $456,740 - $937,670	41,000 New	41,000 $862,000
Q1 2020 May 14, 2020	SELL	$9.44 - $15.58 $346,448 - $571,786	-36,700 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$10.43 - $17.67 $382,781 - $648,489	36,700 New	36,700 $538,000
Q3 2019 Nov 13, 2019	SELL	$13.07 - $18.51 $2.15 Million - $3.05 Million	-164,600 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$13.88 - $18.41 $2.28 Million - $3.03 Million	164,600 New	164,600 $2.7 Million
Q1 2019 May 14, 2019	SELL	$12.79 - $17.62 $2.92 Million - $4.02 Million	-228,000 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$11.39 - $27.13 $2.6 Million - $6.19 Million	228,000 New	228,000 $3.11 Million

Others Institutions Holding NTLA

# of Institutions

319

Shares Held

88.7M

Call Options Held

668K

Put Options Held

865K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.27B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account